SAB Biotherapeutics (SABS) Equity Average (2021 - 2025)
Historic Equity Average for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $88.5 million.
- SAB Biotherapeutics' Equity Average rose 11330.46% to $88.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.5 million, marking a year-over-year increase of 11330.46%. This contributed to the annual value of $41.6 million for FY2024, which is 575.91% down from last year.
- Latest data reveals that SAB Biotherapeutics reported Equity Average of $88.5 million as of Q3 2025, which was up 11330.46% from $16.7 million recorded in Q2 2025.
- SAB Biotherapeutics' Equity Average's 5-year high stood at $88.5 million during Q3 2025, with a 5-year trough of $16.7 million in Q2 2025.
- In the last 5 years, SAB Biotherapeutics' Equity Average had a median value of $36.7 million in 2021 and averaged $37.2 million.
- As far as peak fluctuations go, SAB Biotherapeutics' Equity Average surged by 13739.49% in 2024, and later tumbled by 6621.87% in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Equity Average stood at $36.8 million in 2021, then decreased by 16.23% to $30.8 million in 2022, then grew by 17.63% to $36.3 million in 2023, then dropped by 13.35% to $31.4 million in 2024, then skyrocketed by 181.67% to $88.5 million in 2025.
- Its Equity Average stands at $88.5 million for Q3 2025, versus $16.7 million for Q2 2025 and $23.7 million for Q1 2025.